CEO and 10% Owner Matthew Angel Buys Over $500K in Tempest Therapeutics Stock
TPST sits 34% above its 52-week low of $1.655 on elevated volume (3.2× avg).
Summary
Tempest Therapeutics' CEO, President, and 10% owner, Matthew Angel, purchased over $500,000 in company stock on the open market, signaling strong insider confidence.
Key Events · Ownership and Investor Activity · TPST
-
Significant Insider Purchase
Matthew Angel, the CEO, President, and a 10% owner, acquired 231,482 shares of common stock for a total value of $500,001.12 in an open market transaction.
-
Strong Leadership Conviction
The substantial purchase by a key insider holding multiple leadership roles (CEO, President, Director, 10% Owner) indicates high confidence in the company's valuation and future outlook.
-
Follows Recent Financing
This open market purchase on March 24, 2026, comes just two days after the company announced a private placement agreement on March 23, 2026, to raise $2.0 million, suggesting the CEO's belief in the company's strengthened financial position.
Analysis · TPST · Life Sciences
Matthew Angel, serving as CEO, President, Director, and a 10% owner, made a substantial open market purchase of Tempest Therapeutics stock, acquiring over $500,000 worth of shares. This significant insider buying, representing more than 2% of the company's market capitalization, signals strong conviction from top leadership. The purchase follows closely on the heels of a private placement agreement announced two days prior, suggesting the CEO's confidence in the company's direction and financial stability after securing additional capital. Investors should view this as a highly positive indicator of internal belief in the company's future prospects.
At the time of this filing, TPST was trading at $2.21 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $23.5M. The 52-week trading range was $1.65 to $12.23. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.